To assess the effect of pharmacological inhibition on CAVD progression, Notch1+/- mice were treated with the 5-HT2B receptor antagonist SB204741. The gene discussed is NOTCH1; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.